(a) All T-ALL patients diagnosed by immunophenotypic analyses according to WHO classification; (b) NOTCH1 and FBXW7 mutation identified by direct sequencing of polymerase chain reaction (PCR)-amplified products;
(c) Case studies, review articles, and studies involving fewer than three patients were excluded; (d) Randomized controlled trials to compare immunotherapy versus control therapy and including children and adults; (e) Adequate survival information and patterns of failure data were needed. 
